Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Tumor and Renal Response in Patients with Newly Diagnosed Multiple Mieloma and Renal Failure Treated with Bortezomib and Dexamethasone: Results of a Prospective Phase II Trial from Pethema/GEM

Laura Rosiñol, MD PhD, Albert Oriol, MD, M Jesús Blanchard, Luis Palomera, Maria-Victoria Mateos, Javier De La Rubia, Miguel T Hernandez, MD, Joaquín Díaz-Mediavilla, Jose Mariano Hernandez, Raquel Jiménez, MD, Cristina Motllo, Juan José Lahuerta, MD PhD, Jesus F. San Miguel, Joan Blade

Blood (2014) 124 (21): 4776.

https://doi.org/10.1182/blood.V124.21.4776.4776

Published: 2014

Journal Articles

Observational Prospective Registry for the Assessment of the Clinical Impact of Starting Anti-Myeloma Treatment at Biological Relapse

Adrian Alegre, Merche Gironella, Juan Miguel Bergua, Esther Gonzalez, Fernando Escalante, Alfon Soler, Antonia Sampol, Ana Pilar Gonzalez, Valentin Cabañas, Juan Jose Lahuerta, Aurelio Lopez, Ana Dios, Abelardo Bárez, Antonio Ruiz, David Vilanova, Joaquín Díaz-Mediavilla

Blood (2014) 124 (21): 4765.

https://doi.org/10.1182/blood.V124.21.4765.4765

Published: 2014

Journal Articles

Persistent Benefit of VTD (Bortezomib/Thalidomide/Dexamethasone) As Pretransplant Induction Therapy for Multiple Myeloma: Long-Term Follow-up of a Randomized Phase 3 Pethema/GEM Study

Blood (2014) 124 (21): 3457.

https://doi.org/10.1182/blood.V124.21.3457.3457

Published: 2014

Journal Articles

Kinetics of Response to Bortezomib/Thalidomide/Dexamethasone (VTD) in Multiple Myeloma: Implications for the Choice and Design of Pretransplantation Induction Regimens

Blood (2014) 124 (21): 2108.

https://doi.org/10.1182/blood.V124.21.2108.2108

Published: 2014

Journal Articles

Minimal Residual Diease Evaluation By Flow Cytometry Is a Complementary Tool To Cytogenetics For Treatment Decision In Acute Myeloid Leukemia

Blood (2013) 122 (21): 2576.

https://doi.org/10.1182/blood.V122.21.2576.2576

Published: 2013

Journal Articles

Intensive (2+5) Or Semi-Intensive (FLUGA) Chemotherapy For Patients With Acute Myeloid Leukemia Who Are 70 Years Of Age Or Older

Blood (2013) 122 (21): 2687.

https://doi.org/10.1182/blood.V122.21.2687.2687

Published: 2013

Journal Articles

Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study

Blood (2012) 120 (8): 1589–1596.

https://doi.org/10.1182/blood-2012-02-408922

Published: 2012

Includes: Supplemental data

Journal Articles

High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma

Blood (2012) 119 (3): 687–691.

https://doi.org/10.1182/blood-2011-07-370460

Published: 2012

Includes: Supplemental data

Journal Articles

Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance

Blood (2011) 118 (17): 4547–4553.

https://doi.org/10.1182/blood-2011-04-345801

Published: 2011

Journal Articles

Risk-adapted treatment of acute promyelocytic leukemia based on all- trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome

Blood (2010) 115 (25): 5137–5146.

https://doi.org/10.1182/blood-2010-01-266007

Published: 2010

Journal Articles

Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia

Blood (2009) 114 (1): 148–152.

https://doi.org/10.1182/blood-2008-11-187724

Published: 2009

Journal Articles

Differentiation syndrome in patients with acute promyelocytic leukemia treated with all- trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors

Blood (2009) 113 (4): 775–783.

https://doi.org/10.1182/blood-2008-07-168617

Published: 2009

Journal Articles

A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma

Laura Rosiñol, José Antonio Pérez-Simón, Anna Sureda, Javier de la Rubia, Felipe de Arriba, Juan José Lahuerta, José David González, Joaquín Díaz-Mediavilla, Belén Hernández, Javier García-Frade, Dolores Carrera, Angel León, Miguel Hernández, Pascual Fernández Abellán, Juan Miguel Bergua, Jesús San Miguel, Joan Bladé

Blood (2008) 112 (9): 3591–3593.

https://doi.org/10.1182/blood-2008-02-141598

Published: 2008

Journal Articles

Association between the proliferative rate of neoplastic B cells, their maturation stage, and underlying cytogenetic abnormalities in B-cell chronic lymphoproliferative disorders: analysis of a series of 432 patients

Blood (2008) 111 (10): 5130–5141.

https://doi.org/10.1182/blood-2007-10-119289

Published: 2008

Journal Articles

Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin

Blood (2008) 111 (7): 3395–3402.

https://doi.org/10.1182/blood-2007-07-100669

Published: 2008

Journal Articles

Induction with Fludarabine, Cyclophosphamide and Rituximab Followed by Maintenance with Rituximab: Results of a Prospective Study in 75 Patients (LNHF-03).

Jose F. Tomas, MD, PhD, Carlos Montalban, Joaquin Martinez-Lopez, Jose Paz, Miguel Canales, Joaquin Diaz-Mediavilla, Pedro Sanchez Godoy, Alberto Fdez de Sevilla, Javier Penalver, MDolores Caballero, Elena Prieto, Jose Salar, Raquel de Ona, Javier de la Serna

Blood (2006) 108 (11): 2762.

https://doi.org/10.1182/blood.V108.11.2762.2762

Published: 2006

Journal Articles

Alternating Bortezomib and Dexamethasone as Induction Regimen Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Younger Patients with Multiple Myeloma: Results of a PETHEMA Phase II Trial.

Laura Rosinol, MD, Albert Oriol, MD, M. -Victoria Mateos, MD, Anna Sureda, MD, Joaquin Diaz-Mediavilla, MD, Adrian Alegre, MD, Juan-Jose Lahuerta, MD, Javier De La Rubia, MD, Carlos Herrero, MD, Helgi Van de Velde, MD, J. F. San Miguel, MD, Joan Blade, MD

Blood (2006) 108 (11): 3086.

https://doi.org/10.1182/blood.V108.11.3086.3086

Published: 2006

Journal Articles

Up-Front Treatment of Diffuse Large-B Cell Lymphoma (DLBCL) in Elderly Patients with Rituximab in Combination with CHOP-Like Chemotherapy: A Multicenter Study on the Current Clinical Management.

Miguel A. Canales, MD, PhD, Javier de la Serna, MD, Pilar Sabin, MD, Joaquin Diaz-Mediavilla, MD, Mariano Provencio, MD, Rosa Ayala, MD, Ricardo Perez, MD, Ana Alvarez, MD, Antonio Sanchez, MD, Raquel Gil, Fernando Hernandez-Navarro, MD, PhD

Blood (2005) 106 (11): 4778.

https://doi.org/10.1182/blood.V106.11.4778.4778

Published: 2005

Journal Articles

Additional Chromosome Abnormalities Have No Prognostic Value in Acute Promyelocytic Leukemia Patients Treated with Simultaneous ATRA and Anthracycline-Based Chemotherapy: An Update of the APL96 and APL99 Pethema Protocols.

Blood (2004) 104 (11): 2019.

https://doi.org/10.1182/blood.V104.11.2019.2019

Published: 2004

NARROW

Tumor and Renal Response in Patients with Newly Diagnosed Multiple Mieloma and Renal Failure Treated with Bortezomib and Dexamethasone: Results of a Prospective Phase II Trial from Pethema/GEM

Observational Prospective Registry for the Assessment of the Clinical Impact of Starting Anti-Myeloma Treatment at Biological Relapse

Persistent Benefit of VTD (Bortezomib/Thalidomide/Dexamethasone) As Pretransplant Induction Therapy for Multiple Myeloma: Long-Term Follow-up of a Randomized Phase 3 Pethema/GEM Study

Kinetics of Response to Bortezomib/Thalidomide/Dexamethasone (VTD) in Multiple Myeloma: Implications for the Choice and Design of Pretransplantation Induction Regimens

Minimal Residual Diease Evaluation By Flow Cytometry Is a Complementary Tool To Cytogenetics For Treatment Decision In Acute Myeloid Leukemia

Intensive (2+5) Or Semi-Intensive (FLUGA) Chemotherapy For Patients With Acute Myeloid Leukemia Who Are 70 Years Of Age Or Older

Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study

High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma

Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance

Risk-adapted treatment of acute promyelocytic leukemia based on all- trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome

Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia

Differentiation syndrome in patients with acute promyelocytic leukemia treated with all- trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors

A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma

Association between the proliferative rate of neoplastic B cells, their maturation stage, and underlying cytogenetic abnormalities in B-cell chronic lymphoproliferative disorders: analysis of a series of 432 patients

Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin

Induction with Fludarabine, Cyclophosphamide and Rituximab Followed by Maintenance with Rituximab: Results of a Prospective Study in 75 Patients (LNHF-03).

Alternating Bortezomib and Dexamethasone as Induction Regimen Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Younger Patients with Multiple Myeloma: Results of a PETHEMA Phase II Trial.

Up-Front Treatment of Diffuse Large-B Cell Lymphoma (DLBCL) in Elderly Patients with Rituximab in Combination with CHOP-Like Chemotherapy: A Multicenter Study on the Current Clinical Management.

Additional Chromosome Abnormalities Have No Prognostic Value in Acute Promyelocytic Leukemia Patients Treated with Simultaneous ATRA and Anthracycline-Based Chemotherapy: An Update of the APL96 and APL99 Pethema Protocols.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only